View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Clas...

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; o...

 PRESS RELEASE

American Assets Trust, Inc. Reports Fourth Quarter and Year End 2025 F...

American Assets Trust, Inc. Reports Fourth Quarter and Year End 2025 Financial Results SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “company”) today reported financial results for its fourth quarter and year ended December 31, 2025. Fourth Quarter Highlights Net income available to common stockholders of $3.1 million and $55.6 million for the three months and year ended December 31, 2025, respectively, or $0.05 and $0.92 per diluted share, respectively.FFO of $0.47 and $2.00 per diluted share for the three months and year ended December 3...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Franklin Street Properties Corp. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 26 January 2026 in which we reassessed the appropriateness of the ratings ...

 PRESS RELEASE

American Assets Trust, Inc. Releases Tax Status of 2025 Distributions

American Assets Trust, Inc. Releases Tax Status of 2025 Distributions SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “Company”) announced today the tax treatment of its 2025 dividend distributions as follows: Security Descriptions: Common StockCUSIP: 024013104Ticker Symbol: AAT Record DatePayable DateTotal Distribution Per ShareAllocable to 2025Taxable Ordinary DividendLT Capital GainUnrecaptured Sec. 1250 GainSection 199A DividendsReturn of Capital03/06/2503/20/25$0.340$0.340$0.140480$0.059651$0.042897$0.140480$0.13986906/05/2506/19/25$0.340$0....

 PRESS RELEASE

American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2025...

American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2025 Earnings Release Date and Conference Call Information SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its fourth quarter and year-end 2025 earnings in a press release to be issued after the market closes on Tuesday, February 3, 2026. Senior management will hold a conference call for its fourth quarter and year-end 2025 earnings on Wednesday, February 4, 2026 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 a...

 PRESS RELEASE

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare C...

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco.  Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time. The fireside chat will be webcast live and available for replay in the Investors sectio...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Opko Health Inc: 1 director

A director at Opko Health Inc bought 580,000 shares at 1.326USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

QuidelOrtho Corp: 1 director

A director at QuidelOrtho Corp bought 23,500 shares at 21.344USD and the significance rating of the trade was 97/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

 PRESS RELEASE

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare...

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time. Investors interested in scheduling a meeting with OPKO management should conta...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 31, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

OPKO Health Reports Third Quarter 2025 Business Highlights and Financi...

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s...

 PRESS RELEASE

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration wi...

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multi...

 PRESS RELEASE

American Assets Trust, Inc. Reports Third Quarter 2025 Financial Resul...

American Assets Trust, Inc. Reports Third Quarter 2025 Financial Results Net income available to common stockholders of $4.5 million and $52.5 million for the three and nine months ended September 30, 2025, respectively, or $0.07 and $0.87 per diluted share, respectively. Funds from Operations ("FFO") of $0.49 and $1.53 per diluted share for the three and nine months ended September 30, 2025, respectively. Increased 2025 FFO per diluted share guidance to a range of $1.93 to $2.01 with a midpoint of $1.97, a $0.02 increase over prior guidance. SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch